Business
EpiSwitch used in diagnosis of canine lymphoma
EpiSwitch used in diagnosis of canine lymphoma.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 9235Z Oxford BioDynamics PLC 15 January 2020 \n\n15 January 2020\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nOxford BioDynamics presents results of collaborative work demonstrating first proof of principle for EpiSwitch™ biomarkers in non-invasive diagnosis of canine lymphoma \n \n· Results of a study presented at the AACR Conference on Advances in Liquid Biopsies demonstrate the utility of EpiSwitch™ biomarkers for the diagnosis of canine lymphoma \n· Canine lymphoma accounts for 84% of blood cell malignancies and 24% of all tumours in dogs \n \nOxford BioDynamics Plc, a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, announces that a study focused on the diagnosis of B-cell lymphoma in dogs has been presented at the American Association for Cancer Research (AACR) Conference on Advances in Liquid Biopsies, which is taking place in Miami, Florida, 13-16 January 2020. \n \nOn Tuesday 14 January, OBD presented a paper/poster at the conference entitled: \"Development and validation of diagnostic biomarkers for B-cell lymphoma using EpiSwitch™ profiling of whole blood: from humans to canines\". The study was conducted in collaboration with the University of Minnesota Department of Veterinary Clinical Sciences, Animal Cancer Care and Research Program, College of Veterinary Medicine and Masonic Cancer Center. \n \nOBD utilised its proprietary datasets of markers specific for regulatory 3D genome architecture of lymphoma in humans, as determined using EpiSwitch™, to see if these could be translated from humans into dogs. OBD was able to generate a new biomarker signature using whole blood from a cohort of dogs with lymphoma and validate it on a second cohort. This biomarker signature was able to correctly identify dogs with and without lymphoma with 80% accuracy, 80% sensitivity, 80% specificity, 80% positive predictive value and 80% negative predictive value. \n \nThe results of this study indicate that EpiSwitch™ biomarkers can be successfully translated across species for related pathologies and conditions. This highlights t...